Disruption of biological rhythms as a core problem and therapeutic target in mood disorders: The emerging concept of 'rhythm regulators'

Annals of General Psychiatry

Volumn 9, Issue , 2010, Pages

  Fountoulakis, Konstantinos N ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR;

ANHEDONIA; ANXIETY; BIOLOGICAL RHYTHM; DEPRESSION; EDITORIAL; FATIGUE; HUMAN; INSOMNIA; MOOD DISORDER; PSYCHOMOTOR ACTIVITY; REM SLEEP; REMISSION; SEXUAL FUNCTION; SLEEP AROUSAL DISORDER; SLEEP WAKING CYCLE;

EID: 76749105211     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-9-3     Document Type: Editorial

References (21)

1. McClung CA. Circadian genes, rhythms and the biology of mood disorders. Pharmacol Ther 2007, 114(2):222-232. 10.1016/j.pharmthera.2007.02.003, 1925042, 17395264.
2. Akiskal HS, McKinney WT. Overview of recent research in depression. Integration of ten conceptual models into a comprehensive clinical frame. Arch Gen Psychiatry 1975, 32(3):285-305.
3. Hubain P, Le Bon O, Vandenhende F, Van Wijnendaele R, Linkowski P. Major depression in males: effects of age, severity and adaptation on sleep variables. Psychiatry Res 2006, 145(2-3):169-177. 10.1016/j.psychres.2005.08.027, 17074401.
4. Hammad MA, Barsky AJ, Regestein QR. Correlation between somatic sensation inventory scores and hyperarousal scale scores. Psychosomatics 2001, 42(1):29-34. 10.1176/appi.psy.42.1.29, 11161118.
5. Riemann D, Voderholzer U. Primary insomnia: a risk factor to develop depression?. J Affect Disord 2003, 76(1-3):255-259. 10.1016/S0165-0327(02)00072-1, 12943956.
6. Vgontzas AN, Bixler EO, Lin HM, Prolo P, Mastorakos G, Vela-Bueno A, Kales A, Chrousos GP. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab 2001, 86(8):3787-3794. 10.1210/jc.86.8.3787, 11502812.
7. Joiner TE, Steer RA, Beck AT, Schmidt NB, Rudd MD, Catanzaro SJ. Physiological hyperarousal: construct validity of a central aspect of the tripartite model of depression and anxiety. J Abnorm Psychol 1999, 108(2):290-298. 10.1037/0021-843X.108.2.290, 10369039.
8. Fotiou F, Fountoulakis KN, Iacovides A, Kaprinis G. Pattern-reversed visual evoked potentials in subtypes of major depression. Psychiatry Res 2003, 118(3):259-271. 10.1016/S0165-1781(03)00097-0, 12834820.
9. Gold PW, Chrousos GP. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Proc Assoc Am Physicians 1999, 111(1):22-34. 10.1046/j.1525-1381.1999.09423.x, 9893154.
10. Ehlers CL, Somes C, Seifritz E, Rivier JE. CRF/NPY interactions: a potential role in sleep dysregulation in depression and anxiety. Depress Anxiety 1997, 6(1):1-9. 10.1002/(SICI)1520-6394(1997)6:1<1::AID-DA1>3.0.CO;2-J, 9394869.
11. Bruder GE. P300 findings for depressive and anxiety disorders. Ann N Y Acad Sci 1992, 658:205-222. 10.1111/j.1749-6632.1992.tb22846.x, 1497259.
12. Shagass C, Roemer RA. Evoked potential topography in major depression. II. Comparisons between subgroups. Int J Psychophysiol 1992, 13(3):255-261. 10.1016/0167-8760(92)90075-M, 1459882.
13. Shagass C, Roemer RA. Evoked potential topography in major depression. I. Comparisons with nonpatients and schizophrenics. Int J Psychophysiol 1992, 13(3):241-254. 10.1016/0167-8760(92)90074-L, 1459881.
14. Fountoulakis KN, Karamouzis M, Iacovides A, Nimatoudis J, Diakogiannis J, Kaprinis G, Demitriadou A, Bech P. Morning and evening plasma melatonin and dexamethasone suppression test in patients with nonseasonal major depressive disorder from northern Greece (latitude 40-41.5 degrees ). Neuropsychobiology 2001, 44(3):113-117. 10.1159/000054928, 11586048.
15. Souetre E, Salvati E, Belugou JL, Pringuey D, Candito M, Krebs B, Ardisson JL, Darcourt G. Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Res 1989, 28(3):263-278. 10.1016/0165-1781(89)90207-2, 2762432.
16. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003, 17(2):149-173. discussion 147, 10.1177/0269881103017002003, 12870562.
17. Montgomery DB. ECNP Consensus Meeting March 2000 Nice: guidelines for investigating efficacy in bipolar disorder. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol 2001, 11(1):79-88. 10.1016/S0924-977X(00)00140-1, 11300094.
18. Calabrese J, Rapport D. Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder. Journal of Clinical Psychiatry 1999, 60:5-13.
19. Bowden C. New concepts in mood stabilization. Neuropsychopharmacology 1998, 19:194-199. 10.1016/S0893-133X(98)00025-6, 9653707.
20. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007, 68(11):1723-1732. 10.4088/JCP.v68n1112, 18052566.
21. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008, 28(3):329-333. 10.1097/JCP.0b013e318172b48c, 18480691.